Therapies that are beneficial for HF (such as beta blockers or angiotensin converting enzyme inhibitors) tend to lower levels of NT-proBNP in parallel with improvements in outcomes of patients so treated.
Nt-proBNP levels may identify a patient at high risk for adverse outcome from their HF, even in periods of apparent stability.